[{"address1": "121 South Orange Avenue", "address2": "Suite 1500", "city": "Orlando", "state": "FL", "zip": "32801", "country": "United States", "phone": "407 377 6695", "website": "https://nutriband.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Serguei  Melnik", "age": 49, "title": "Founder, President, Company Secretary & Executive Chairman of the Board", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 175000, "exercisedValue": 0, "unexercisedValue": 34300}, {"maxAge": 1, "name": "Mr. Gareth  Sheridan", "age": 33, "title": "Founder, CEO & Director", "yearBorn": 1990, "fiscalYear": 2024, "totalPay": 175000, "exercisedValue": 0, "unexercisedValue": 34300}, {"maxAge": 1, "name": "Mr. Gerald  Goodman", "age": 75, "title": "CFO & Chief Accounting Officer", "yearBorn": 1948, "fiscalYear": 2024, "totalPay": 140000, "exercisedValue": 0, "unexercisedValue": 93160}, {"maxAge": 1, "name": "Dr. Alan  Smith Ph.D.", "age": 57, "title": "COO & President of 4P Therapeutics", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 159000, "exercisedValue": 0, "unexercisedValue": 27200}, {"maxAge": 1, "name": "Dr. Jeffrey  Patrick Pharm.D.", "age": 53, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 2345}, {"maxAge": 1, "name": "Mr. Michael  Myer", "age": 38, "title": "President of Pocono Pharmaceutical", "yearBorn": 1985, "fiscalYear": 2024, "totalPay": 40600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tyler  Overk", "age": 39, "title": "Head of Active Intelligence", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "previousClose": 4.89, "open": 4.85, "dayLow": 4.38, "dayHigh": 4.9986, "regularMarketPreviousClose": 4.89, "regularMarketOpen": 4.85, "regularMarketDayLow": 4.38, "regularMarketDayHigh": 4.9986, "beta": 0.509, "forwardPE": -19.542608, "volume": 18343, "regularMarketVolume": 18343, "averageVolume": 51917, "averageVolume10days": 45920, "averageDailyVolume10Day": 45920, "bid": 3.5, "ask": 5.93, "bidSize": 200, "askSize": 200, "marketCap": 49307508, "fiftyTwoWeekLow": 1.53, "fiftyTwoWeekHigh": 6.0, "priceToSalesTrailing12Months": 23.645124, "fiftyDayAverage": 3.66328, "twoHundredDayAverage": 2.89648, "currency": "USD", "enterpriseValue": 52903712, "profitMargins": -2.6304502, "floatShares": 6716099, "sharesOutstanding": 10969900, "sharesShort": 19353, "sharesShortPriorMonth": 36264, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.0018000001, "heldPercentInsiders": 0.449, "heldPercentInstitutions": 0.02313, "shortRatio": 0.46, "shortPercentOfFloat": 0.0036000002, "impliedSharesOutstanding": 10969900, "bookValue": 0.727, "priceToBook": 6.1826687, "lastFiscalYearEnd": 1706659200, "nextFiscalYearEnd": 1738281600, "mostRecentQuarter": 1706659200, "netIncomeToCommon": -5485314, "trailingEps": -0.69, "forwardEps": -0.23, "lastSplitFactor": "1166:1000", "lastSplitDate": 1660262400, "enterpriseToRevenue": 25.37, "enterpriseToEbitda": -11.54, "52WeekChange": 0.469697, "SandP52WeekChange": 0.28043115, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "NTRB", "underlyingSymbol": "NTRB", "shortName": "Nutriband Inc.", "longName": "Nutriband Inc.", "firstTradeDateEpochUtc": 1633095000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9917d47e-ab3c-342f-8efa-c0a2da24da68", "messageBoardId": "finmb_345353860", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.4948, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 492942, "totalCashPerShare": 0.045, "ebitda": -4584204, "totalDebt": 241285, "quickRatio": 0.642, "currentRatio": 1.023, "totalRevenue": 2085314, "debtToEquity": 3.748, "revenuePerShare": 0.262, "returnOnAssets": -0.35879, "returnOnEquity": -0.73083, "freeCashflow": -1794245, "operatingCashflow": -3527509, "revenueGrowth": -0.006, "grossMargins": 0.41342, "ebitdaMargins": -2.19833, "operatingMargins": -2.49012, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-21"}]